Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis
Eighty-five percent of multiple sclerosis cases begin with a discrete attack termed clinically isolated syndrome, but 37% of clinically isolated syndrome patients do not experience a relapse within 20 years of onset. Thus, the identification of biomarkers able to differentiate between ind...
Main Authors: | Probert, F, Yeo, T, Zhou, Y, Sealey, M, Arora, S, Palace, J, Claridge, TDW, Hillenbrand, R, Oechtering, J, Leppert, D, Kuhle, J, Anthony, DC |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Oxford University Press
2021
|
Similar Items
-
Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach
by: Yeo, T, et al.
Published: (2021) -
Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands
by: Probert, F, et al.
Published: (2022) -
Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model
by: Yeo, T, et al.
Published: (2022) -
The longitudinal cerebrospinal fluid metabolomic profile of amyotrophic lateral sclerosis.
by: Gray, E, et al.
Published: (2015) -
A blood-based metabolomics test to distinguish relapsing–remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application
by: Yeo, T, et al.
Published: (2020)